[go: up one dir, main page]

AR019724A2 - PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF MELLITUS DIABETES AND ASSOCIATED CONDITIONS - Google Patents

PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF MELLITUS DIABETES AND ASSOCIATED CONDITIONS

Info

Publication number
AR019724A2
AR019724A2 ARP990103110A ARP990103110A AR019724A2 AR 019724 A2 AR019724 A2 AR 019724A2 AR P990103110 A ARP990103110 A AR P990103110A AR P990103110 A ARP990103110 A AR P990103110A AR 019724 A2 AR019724 A2 AR 019724A2
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical composition
composition useful
associated conditions
mellitus diabetes
Prior art date
Application number
ARP990103110A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR019724A2 publication Critical patent/AR019724A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Una composicion farmacéutica que comprende un sensibilizador a insulina, un secretagogo de insulina, un agente antihiperglucémico inhibidor dealfa-glucosidasa, y un vehículo farmacéuticamente aceptable, util para el tratamiento de la diabetes mellitus y las condiciones asociadas con la diabetesmellitus en un mamífero.A pharmaceutical composition comprising an insulin sensitizer, an insulin secretagogue, an anti-hyperglycemic agent anti-glucosidase inhibitor, and a pharmaceutically acceptable carrier, useful for the treatment of diabetes mellitus and the conditions associated with diabetesmellitus in a mammal.

ARP990103110A 1997-07-18 1999-06-28 PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF MELLITUS DIABETES AND ASSOCIATED CONDITIONS AR019724A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
AR019724A2 true AR019724A2 (en) 2002-03-13

Family

ID=10816170

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980103482A AR016350A1 (en) 1997-07-18 1998-07-16 USE OF AN INSULIN SENSITIZER, AN INSULIN SECRETAGOG AND AN ALFA-GLUCOSIDASE INHIBITING ANTI-HERITAGE AGENT TO PREPARE MEDICATIONS
ARP990103110A AR019724A2 (en) 1997-07-18 1999-06-28 PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF MELLITUS DIABETES AND ASSOCIATED CONDITIONS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980103482A AR016350A1 (en) 1997-07-18 1998-07-16 USE OF AN INSULIN SENSITIZER, AN INSULIN SECRETAGOG AND AN ALFA-GLUCOSIDASE INHIBITING ANTI-HERITAGE AGENT TO PREPARE MEDICATIONS

Country Status (27)

Country Link
EP (1) EP1001784A1 (en)
JP (1) JP2001510160A (en)
KR (1) KR20010021952A (en)
CN (1) CN1263467A (en)
AP (1) AP2000001735A0 (en)
AR (2) AR016350A1 (en)
AU (1) AU8449098A (en)
BG (1) BG104062A (en)
BR (1) BR9810292A (en)
CA (1) CA2297133A1 (en)
CO (1) CO4940489A1 (en)
DZ (1) DZ2563A1 (en)
EA (1) EA200000140A1 (en)
GB (1) GB9715298D0 (en)
HU (1) HUP0003626A3 (en)
ID (1) ID23804A (en)
IL (1) IL133907A0 (en)
MA (1) MA24608A1 (en)
NO (1) NO20000230L (en)
OA (1) OA11312A (en)
PE (1) PE99499A1 (en)
PL (1) PL338140A1 (en)
SK (1) SK612000A3 (en)
TR (1) TR200000133T2 (en)
UY (1) UY25101A1 (en)
WO (1) WO1999003478A1 (en)
ZA (1) ZA986364B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000078333A2 (en) * 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
DE60132723T2 (en) * 2000-01-21 2009-01-29 Novartis Pharma Ag Compositions consisting of dipeptidyl peptidase IV inhibitors and antidiabetics
WO2001062295A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Drugs containing combined active ingredients
JP4917712B2 (en) * 2000-02-24 2012-04-18 武田薬品工業株式会社 Concomitant medication
PL362687A1 (en) 2001-01-12 2004-11-02 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2832930A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES
KR100952090B1 (en) 2003-10-31 2010-04-13 다케다 야쿠힌 고교 가부시키가이샤 Solid preparations containing insulin sensitizers, insulin secretagogues and polyoxyethylene sorbitan fatty acid esters
CN101103993B (en) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 Hypoglycemic medicine composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003724A1 (en) * 1991-08-26 1993-03-04 The Upjohn Company Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
EA200000140A1 (en) 2000-06-26
JP2001510160A (en) 2001-07-31
EP1001784A1 (en) 2000-05-24
NO20000230D0 (en) 2000-01-17
GB9715298D0 (en) 1997-09-24
ID23804A (en) 2000-05-11
CA2297133A1 (en) 1999-01-28
TR200000133T2 (en) 2000-09-21
KR20010021952A (en) 2001-03-15
IL133907A0 (en) 2001-04-30
CN1263467A (en) 2000-08-16
AR016350A1 (en) 2001-07-04
AP2000001735A0 (en) 2000-01-16
HUP0003626A3 (en) 2001-12-28
PL338140A1 (en) 2000-09-25
OA11312A (en) 2003-10-24
BG104062A (en) 2000-11-30
HUP0003626A2 (en) 2001-05-28
NO20000230L (en) 2000-01-17
MA24608A1 (en) 1999-04-01
AU8449098A (en) 1999-02-10
PE99499A1 (en) 1999-12-18
ZA986364B (en) 2000-01-17
UY25101A1 (en) 2000-12-29
BR9810292A (en) 2000-09-19
SK612000A3 (en) 2000-07-11
DZ2563A1 (en) 2003-02-15
CO4940489A1 (en) 2000-07-24
WO1999003478A1 (en) 1999-01-28

Similar Documents

Publication Publication Date Title
AR012998A1 (en) USE OF AN INSULIN SENSITIZER AND AN ANTI-HYPERGLYCEMIC AGENT FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH SENSITIZER AND SUCH AGENT.
EA200100541A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED SURVIVAL OF THE SENSITIZER TO INSULIN AND OTHER ANTI-DIABETIC AGENTS
CL2009001899A1 (en) Pharmaceutical composition comprising: i) an at1 receptor antagonist or a salt, ii) an insulin sensitizer or a salt and iii) a pharmaceutically acceptable carrier; use for the prevention, delay of progress or treatment of hypertension, diabetes, among others (div. sol. 2034-01).
AR019724A2 (en) PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF MELLITUS DIABETES AND ASSOCIATED CONDITIONS
AR046210A1 (en) SOLID PREPARATION
UY25798A1 (en) PHARMACEUTICAL COMPOSITION OF MODIFIED RELEASE INCLUDING A THIAZOLIDINADIONIC INSULIN SENSITIZER.
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
CO4940454A1 (en) NEW METHOD OF TREATMENT
UY25103A1 (en) COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS
AR008025A1 (en) PHARMACEUTICAL COMBINATION OF A THIAZOLIDINDIONA AND AN INSULIN SECRETOGOGUE
AR013352A1 (en) USE OF AN INSULIN SENSITIZER AND AN ANTI-HYPERGLYCEMIC AGENT FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF DIABETES MELLITUS AND CONDITIONS ASSOCIATED WITH IT AND A PHARMACEUTICAL COMPOSITION.
HK1041201A1 (en) Compatibility of beta agonists and antidiabetic agents
ECSP982593A (en) NEW METHOD OF TREATMENT VI
ECSP993215A (en) NEW COMPOSITION AND USE
ECSP982591A (en) NEW METHOD OF TREATMENT IV
ECSP982535A (en) NEW TREATMENT METHOD (I)
UY25801A1 (en) PROCEDURE FOR PREPARING COMPOSITIONS FOR THE TREATMENT OF DIABETES.
ES2061942T3 (en) PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
ECSP982542A (en) NEW METHOD OF TREATMENT III
ECSP982592A (en) NEW METHOD OF TREATMENT V
AR010343A1 (en) USE OF 17 BETA-DIHYDROEKYLENINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF 17 BETA-DIHYDROEKYLENINE-3-SULPHATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AS ANTIOXIDANT AND PHARMACEUTICAL COMPOSITION.
ECSP993216A (en) NEW COMPOSITION AND USE II
ECSP982534A (en) NEW METHOD OF TREATMENT